
    
      This is an open-label, single arm, dose escalation study in patients with relapsed or
      refractory AML or MDS. Treatment will be administered on an outpatient basis and all patients
      will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in
      combination with venetoclax. One treatment cycle is 4 weeks.
    
  